CTA (Technological Corporation of Andalusia) has organized today, in collaboration with the European project P5 Innobroker, a technical conference on “problems and solutions for the clinical management of irritable bowel syndrome”.
The prevalence of irritable bowel syndrome (IBS) is 10 to 20% of the general population, it has a great impact on quality of life and produces high costs to health systems. Multiple pathophysiological factors are involved, such as alterations in motility, inflammation, psychological disorders and visceral hypersensitivity, among others. Currently, IBS is a condition that is diagnosed by ruling out other pathologies and the set of persistent symptoms suffered by the patient. The role of some factors such as intestinal permeability, food hypersensitivity and the microbiome is beginning to be seen as important factors that trigger this condition, but currently there is no diagnostic test that identifies it or is used to monitor the evolution of the disease.
The event, organized by CTA and P5 Innobroker, brought together prestigious clinical experts who shared knowledge about the challenge of diagnosing and monitoring IBS. It analyzed how the industry is addressing this disorder, presenting innovative solutions that are revolutionizing gastrointestinal care.
In addition, opportunities for public/private collaboration and Public Procurement of Innovation (PPI) in this area were analyzed and the Progreso y Salud Foundation explained its approach to promoting innovation in Andalusia.
CTA CPI expert and coordinator of the European P5 Innobroker project, Carlos García, explained opportunities to support the procurement of innovative solutions by public buyers. P5 Innobroker is a project financed by the Cosme program and considered strategic by the European Commission that aims to promote the Public Purchase of Innovation in Southern Europe.
Representatives of the Virgen Macarena and Virgen del Rocío public hospitals participated in a panel on irritable bowel syndrome and its impact on healthcare, while representatives of Biomedal, Labsur, Teletest and Xenogene explained their respective innovative solutions.
